Search

Your search keyword '"Sutherland, Rebecca K"' showing total 29 results
Start Over Author "Sutherland, Rebecca K"
29 results on '"Sutherland, Rebecca K"'

2. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Author

Emary, Katherine R W, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Cox, Tony, Darton, Thomas C, Dold, Christina, Douglas, Alexander D, Duncan, Christopher J A, Ewer, Katie J, Flaxman, Amy L, Faust, Saul N, Ferreira, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie G, Minassian, Angela M, McGregor, Alastair C, Mujadidi, Yama F, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David P J, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian V S, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, and Pollard, Andrew J

Published
2021
Full Text
View/download PDF

3. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Author

Aban, Marites, Abeyskera, Kushala W.M., Aboagye, Jeremy, Adam, Matthew, Adams, Kirsty, Adamson, James P., Adewatan, Gbadebo, Adlou, Syed, Ahmed, Khatija, Akhalwaya, Yasmeen, Akhalwaya, Saajida, Alcock, Andrew, Ali, Aabidah, Allen, Elizabeth R., Allen, Lauren, Alvernaz, Felipe B., Amorim, Fabio Santos, Andrade, Claudia Sala, Andritsou, Foteini, Anslow, Rachel, Arbe-Barnes, Edward H., Ariaans, Mark P., Arns, Beatriz, Arruda, Laiana, Assad, Luiza, Azi, Paula De Almeida, Azi, Lorena De Almeida, Babbage, Gavin, Bailey, Catherine, Baker, Kenneth F., Baker, Megan, Baker, Natalie, Baker, Philip, Baleanu, Ioana, Bandeira, Danieli, Bara, Anna, Barbosa, Marcella A.S., Barker, Debbie, Barlow, Gavin D., Barnes, Eleanor, Barr, Andrew S., Barrett, Jordan R., Barrett, Jessica, Barrett, Kelly, Bates, Louise, Batten, Alexander, Beadon, Kirsten, Beales, Emily, Beckley, Rebecca, Belij-Rammerstorfer, Sandra, Bell, Jonathan, Bellamy, Duncan, Belton, Sue, Berg, Adam, Bermejo, Laura, Berrie, Eleanor, Berry, Lisa, Berzenyi, Daniella, Beveridge, Amy, Bewley, Kevin R., Bharaj, Inderjeet, Bhikha, Sutika, Bhorat, Asad E., Bhorat, Zaheda E., Bijker, Else Margreet, Birch, Sarah, Birch, Gurpreet, Birchall, Kathryn, Bird, Adam, Bird, Olivia, Bisnauthsing, Karen, Bittaye, Mustapha, Blackwell, Luke, Blacow, Rachel, Bletchly, Heather, Blundell, Caitlin L., Blundell, Susannah R., Bodalia, Pritesh, Bolam, Emma, Boland, Elena, Bormans, Daan, Borthwick, Nicola, Bowring, Francesca, Boyd, Amy, Bradley, Penny, Brenner, Tanja, Bridges-Webb, Alice, Brown, Phillip, Brown, Claire, Brown-O'Sullivan, Charlie, Bruce, Scott, Brunt, Emily, Budd, William, Bulbulia, Yusuf A., Bull, Melanie, Burbage, Jamie, Burn, Aileen, Buttigieg, Karen R., Byard, Nicholas, Cabrera Puig, Ingrid, Calvert, Anna, Camara, Susana, Cao, Michelangelo, Cappuccini, Federica, Cardona, Rita, Cardoso, João R., Carr, Melanie, Carroll, Miles W., Carson-Stevens, Andrew, Carvalho, Yasmin de M., Casey, Helen R., Cashen, Paul, Castro, Thais R.Y., Castro, Lucia Carratala, Cathie, Katrina, Cavey, Ana, Cerbino-Neto, José, Cezar, Luiz Fernando F., Chadwick, Jim, Chanice, Chanice, Chapman, David, Charlton, Sue, Cheliotis, Katerina S., Chelysheva, Irina, Chester, Oliver, Chiplin, Emily, Chita, Sunder, Cho, Jee-Sun, Cifuentes, Liliana, Clark, Elizabeth, Clark, Matthew, Colin-Jones, Rachel, Collins, Sarah L.K., Colton, Hayley, Conlon, Christopher P., Connarty, Sean, Coombes, Naomi, Cooper, Cushla, Cooper, Rachel, Cornelissen, Lynne, Corrah, Tumena, Cosgrove, Catherine A., Costa, Fernanda Barroso, Cox, Tony, Crocker, Wendy E.M., Crosbie, Sarah, Cullen, Dan, Cunha, Debora R.M.F., Cunningham, Christina J., Cuthbertson, Fiona C., da Costa, Daniel Marinho, Da Guarda, Suzete N. Farias, da Silva, Larissa P., da Silva Moraes, Antonio Carlos, Damratoski, Brad E., Danos, Zsofia, Dantas, Maria T.D.C., Datoo, Mehreen S., Datta, Chandrabali, Davids, Malika, Davies, Sarah L., Davies, Kelly, Davies, Hannah, Davies, Sophie, Davies, Judith, Davis, Elizabeth J., Davis, John, de Carvalho, José A.M., De Jager, Jeanne, de Jesus Jnr, Sergio, De Oliveira Kalid, Lis Moreno, Dearlove, David, Demissie, Tesfaye, Desai, Amisha, Di Marco, Stefania, Di Maso, Claudio, Dinesh, Tanya, Docksey, Claire, Dong, Tao, Donnellan, Francesca R., Dos Santos, Tannyth Gomes, Dos Santos, Thainá G., Dos Santos, Erika Pachecho, Douglas, Naomi, Downing, Charlotte, Drake, Jonathan, Drake-Brockman, Rachael, Drury, Ruth, Du Plessis, Joan, Dunachie, Susanna J., Duncan, Andrew, Easom, Nicholas J.W., Edwards, Mandy, Edwards, Nick J., Edwards, Frances, El Muhanna, Omar M., Elias, Sean C., Ellison-Handley, Branwen, Elmore, Michael J., English, Marcus Rex, Esmail, Alisgair, Essack, Yakub Moosa, Farooq, Mutjaba, Fedosyuk, Sofiya, Felle, Sally, Ferguson, Susie, Ferreira Da Silva, Carla, Field, Samantha, Fisher, Richard, Fletcher, James, Fofie, Hazel, Fok, Henry, Ford, Karen J., Fothergill, Ross, Fowler, Jamie, Fraiman, Pedro H.A., Francis, Emma, Franco, Marilia M., Frater, John, Freire, Marilúcia S.M., Fry, Samantha H., Fudge, Sabrina, Furlan Filho, Renato, Furze, Julie, Fuskova, Michelle, Galian-Rubio, Pablo, Garlant, Harriet, Gavrila, Madita, Gibbons, Karyna A., Gilbride, Ciaran, Gill, Hardeep, Godwin, Kerry, Gokani, Karishma, Gonçalves, Maria Luisa Freire, Gonzalez, Isabela G.S., Goodall, Jack, Goodwin, Jayne, Goondiwala, Amina, Gordon-Quayle, Katherine, Gorini, Giacomo, Goyanna, Alvaro, Grab, Janet, Gracie, Lara, Green, Justin, Greenwood, Nicola, Greffrath, Johann, Groenewald, Marisa M., Gunawardene, Anishka, Gupta, Gaurav, Hackett, Mark, Hallis, Bassam, Hamaluba, Mainga, Hamilton, Elizabeth, Hamlyn, Joseph, Hammersley, Daniel, Hanrath, Aidan T., Hanumunthadu, Brama, Harris, Stephanie A., Harris, Clair, Harrison, Thomas D., Harrison, Daisy, Harris-Wright, Tara A., Hart, Thomas C., Hartnell, Birgit, Haughney, John, Hawkins, Sophia, Hayano, Laís Y.M., Head, Ian, Heath, Paul T., Henry, John Aaron, Hermosin Herrera, Macarena, Hettle, David B., Higa, Cristhiane, Hill, Jennifer, Hodges, Gina, Hodgson, Susanne, Horne, Elizea, Hou, Mimi M., Houlihan, Catherine F., Howe, Elizabeth, Howell, Nicola, Humphreys, Jonathan, Humphries, Holly E., Hurley, Katrina, Huson, Claire, Hyams, Catherine, Hyder-Wright, Angela, Ikram, Sabina, Ishwarbhai, Alka, Iveson, Poppy, Iyer, Vidyashankara, Jackson, Frederic, Jackson, Susan, Jaumdally, Shameem, Jeffers, Helen, Jesudason, Natasha, Jones, Carina, Jones, Christopher, Jones, Kathryn, Jones, Elizabeth, Jorge, Marianna Rocha, Joshi, Amar, Júnior, Eduardo A.M.S., Kailath, Reshma, Kana, Faeeza, Kar, Arnab, Karampatsas, Konstantinos, Kasanyinga, Mwila, Kay, Linda, Keen, Jade, Kellett Wright, Johanna, Kelly, Elizabeth J., Kelly, Debbie, Kelly, Dearbhla M., Kelly, Sarah, Kerr, David, Khan, Liaquat, Khozoee, Baktash, Khurana, Ankush, Kidd, Sarah, Killen, Annabel, Kinch, Jasmin, Kinch, Patrick, King, Lloyd D.W., King, Thomas B., Kingham, Lucy, Klenerman, Paul, Kluczna, Diana M., Knapper, Francesca, Knight, Julian C., Knott, Daniel, Koleva, Stanislava, Lages, Pedro M., Lang, Matilda, Lang, Gail, Larkworthy, Colin W., Larwood, Jessica P.J., Law, Rebecca, Lawrie, Alison M., Lazarus, Erica M., Leach, Amanda, Lees, Emily A., Lelliott, Alice, Lemm, Nana-Marie, Lessa, Alvaro Edson Ramos, Leung, Stephanie, Li, Yuanyuan, Lias, Amelia M., Liatsikos, Konstantinos, Linder, Aline, Lipworth, Samuel, Liu, Shuchang, Liu, Xinxue, Lloyd, Adam, Lloyd, Stephanie, Loew, Lisa, Lopez Ramon, Raquel, Lora, Leandro Bonecker, Luz, Kleber Giovanni, MacDonald, Jonathan C., MacGregor, Gordon, Madhavan, Meera, Mainwaring, David O., Makambwa, Edson, Makinson, Rebecca, Malahleha, Mookho, Malamatsho, Ross, Mallett, Garry, Manning, Nicola, Mansatta, Kushal, Maoko, Takalani, Marinou, Spyridoula, Marlow, Emma, Marques, Gabriela N., Marriott, Paula, Marshall, Richard P., Marshall, Julia L., Masenya, Masebole, Masilela, Mduduzi, Masters, Shauna K., Mathew, Moncy, Matlebjane, Hosea, Matshidiso, Kedidimetse, Mazur, Olga, Mazzella, Andrea, McCaughan, Hugh, McEwan, Joanne, McGlashan, Joanna, McInroy, Lorna, McRobert, Nicky, McSwiggan, Steve, Megson, Clare, Mehdipour, Savviz, Meijs, Wilma, Mendonça, Renata N.Õ., Mentzer, Alexander J., Mesquita, Ana Carolina F., Miralhes, Patricia, Mirtorabi, Neginsadat, Mitton, Celia, Mnyakeni, Sibusiso, Moghaddas, Fiona, Molapo, Kgaogelo, Moloi, Mapule, Moore, Maria, Moran, Marni, Morey, Ella, Morgans, Róisín, Morris, Susan J., Morris, Sheila, Morrison, Hazel, Morselli, Franca, Morshead, Gertraud, Morter, Richard, Mottay, Lynelle, Moultrie, Andrew, Moyo, Nathifa, Mpelembue, Mushiya, Msomi, Sibekezelo, Mugodi, Yvonne, Mukhopadhyay, Ekta, Muller, Jilly, Munro, Alasdair, Murphy, Sarah, Mweu, Philomena, Myerscough, Christopher, Naik, Gurudutt, Naker, Kush, Nastouli, Eleni, Ndlovu, Bongani, Nikolaou, Elissavet, Njenga, Cecilia, Noal, Helena C., Noé, Andrés, Novaes, Gabrielle, Nugent, Fay L., Nunes, Géssika Lanzillo A., O'Brien, Katie, O'Connor, Daniel, Oelofse, Suzette, Oguti, Blanche, Olchawski, Victoria, Oldfield, Neil J., Oliveira, Marianne G., Oliveira, Catarina, Oliveira, Isabelle Silva Queiroz, Oommen-Jose, Aylin, Oosthuizen, Angela, O'Reilly, Paula, O'Reilly, Peter J., Osborne, Piper, Owen, David R.J., Owen, Lydia, Owens, Daniel, Owino, Nelly, Pacurar, Mihaela, Paiva, Brenda V.B., Palhares, Edna M.F., Palmer, Susan, Parracho, Helena M. R.T., Parsons, Karen, Patel, Dipak, Patel, Bhumika, Patel, Faeezah, Patrick-Smith, Maia, Payne, Ruth O., Peng, Yanchun, Penn, Elizabeth J., Pennington, Anna, Peralta Alvarez, Marco Polo, Pereira Stuchi, Bruno Pereira, Perez, Ana Luiza, Perinpanathan, Tanaraj, Perring, James, Perumal, Rubeshan, Petkar, Sahir Yusuf, Philip, Tricia, Phillips, Jennifer, Phohu, Mary Kgomotso, Pickup, Lorinda, Pieterse, Sonja, Pinheiro, Jessica Morgana, Piper, Jo, Pipini, Dimitra, Plank, Mary, Plant, Sinéad, Pollard, Samuel, Pooley, Jennifer, Pooran, Anil, Poulton, Ian, Powers, Claire, Presa, Fernando B., Price, David A., Price, Vivien, Primeira, Marcelo R., Proud, Pamela C., Provstgaard-Morys, Samuel, Pueschel, Sophie, Pulido, David, Quaid, Sheena, Rabara, Ria, Radia, Kajal, Rajapaska, Durga, Rajeswaran, Thurkka, Ramos, Leonardo, Ramos, Alberto San Francisco, Ramos Lopez, Fernando, Rampling, Tommy, Rand, Jade, Ratcliffe, Helen, Rawlinson, Tom, Rea, David, Rees, Byron, Resuello-Dauti, Mila, Reyes Pabon, Emilia, Rhead, Sarah, Riaz, Tawassal, Ricamara, Marivic, Richards, Alexander, Richter, Alex, Ritchie, Neil, Ritchie, Adam J., Robbins, Alexander J., Roberts, Hannah, Robinson, Ryan E., Roche, Sophie, Rollier, Christine, Rose, Louisa, Ross Russell, Amy L., Rossouw, Lindie, Royal, Simon, Rudiansyah, Indra, Ryalls, Kim, Sabine, Charlotte, Saich, Stephen, Sale, Jessica C., Salman, Ahmed M., Salvador, Natalia, Salvador, Stephannie, Sampaio, Milla Dias, Samson, Annette D., Sanchez-Gonzalez, Amada, Sanders, Helen, Sanders, Katherine, Santos, Erika, Santos Guerra, Mayara F.S., Satti, Iman, Saunders, Jack E., Saunders, Caroline, Sayed, Aakifah Bibi Arif, Schim van der Loeff, Ina, Schmid, Annina B., Schofield, Ella, Screaton, Gavin R., Seddiqi, Samiullah, Segireddy, Rameswara R., Senger, Roberta, Serrano, Sonia, Shaik, Imam, Sharpe, Hannah R., Sharrocks, Katherine, Shaw, Robert, Shea, Adam, Sheehan, Emma, Shepherd, Amy, Shiham, Farah, Silk, Sarah E., Silva-Reyes, Laura, Silveira, Lidiana B. T.D., Silveira, Mariana B.V., Singh, Nisha, Sinha, Jaisi, Skelly, Donal T., Smith, Daniel C., Smith, Nick, Smith, Holly E., Smith, David J., Smith, Catherine C., Soares, Airanuédida S., Solórzano, Carla, Sorio, Guilherme L., Sorley, Kim, Sosa-Rodriguez, Tiffany, Souza, Cinthia M.C.D.L., Souza, Bruno S.D.F., Souza, Alessandra R., Souza Lopez, Thamyres, Sowole, Luciana, Spencer, Alexandra J., Spoors, Louise, Stafford, Lizzie, Stamford, Imogen, Stein, Ricardo, Stockdale, Lisa, Stockwell, Lisa V., Strickland, Louise H., Stuart, Arabella, Sturdy, Ann, Sutton, Natalina, Szigeti, Anna, Tahiri-Alaoui, Abdessamad, Tanner, Rachel, Taoushanis, Carol, Tarr, Alexander W., Tarrant, Richard, Taylor, Keja, Taylor, Ursula, Taylor, Iona Jennifer, Taylor, Justin, te Water Naude, Rebecca, Templeton, Kate, Themistocleous, Yrene, Themistocleous, Andreas, Thomas, Merin, Thomas, Kelly, Thomas, Tonia M., Thombrayil, Asha, Thompson, Julia, Thompson, Fawziyah, Thompson, Ameeka, Thompson, Amber, Thompson, Kevin, Thornton-Jones, Viv, Thotusi, Larissa H.S., Tighe, Patrick J., Tinoco, Lygia Accioly, Tiongson, Gerlynn Ferreras, Tladinyane, Bonolo, Tomasicchio, Michele, Tomic, Adriana, Tonks, Susan, Towner, James, Tran, Nguyen, Tree, Julia A., Trillana, Gerry, Trinham, Charlotte, Trivett, Rose, Truby, Adam, Tsheko, Betty Lebogang, Tubb, Philippa, Turabi, Aadil, Turner, Richard, Turner, Cheryl, Turner, Nicola, Tyagi, Bhavya, Ulaszewska, Marta, Underwood, Benjamin R., van Eck, Samual, Varughese, Rachel, Verbart, Dennis, Verheul, Marije K., Vichos, Iason, Vieira, Taiane A., Walker, Gemma, Walker, Laura, Wand, Matthew E., Wardell, Theresa, Warimwe, George M., Warren, Sarah C., Watkins, Bridget, Watson, Marion E.E., Watson, Ekaterina, Webb, Stewart, Webster, Angela, Welch, Jessica, Wellbelove, Zoe, Wells, Jeanette H., West, Alison J., White, Beth, White, Caroline, White, Rachel, Williams, Paul, Williams, Rachel L., Willingham, Silvia, Winslow, Rebecca, Woods, Danielle, Woodyer, Mark, Worth, Andrew T., Wright, Danny, Wroblewska, Marzena, Yao, Andy, Yim, Yee Ting Nicole, Zambrano, Marina Bauer, Zimmer, Rafael Leal, Zizi, Dalila, Zuidewind, Peter, Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Y, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian, Baillie, Vicky L, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth A, Collins, Andrea M, Cutland, Clare L, Darton, Thomas C, Dheda, Keertan, Dold, Christina, Duncan, Christopher J A, Emary, Katherine R W, Ewer, Katie J, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Joe, Carina C D, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie G, Marshall, Richard P, Mendes, Ana V A, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair, Mujadidi, Yama F, Nana, Anusha, Padayachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Ritchie, Adam J, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, M Estée, Toshner, Mark, Turner, David P J, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Douglas, Alexander D, Hill, Adrian V S, Lambe, Teresa, Gilbert, Sarah C, and Pollard, Andrew J

Published
2021
Full Text
View/download PDF

4. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Author

Aban, Marites, Abayomi, Fatola, Abeyskera, Kushala, Aboagye, Jeremy, Adam, Matthew, Adams, Kirsty, Adamson, James, Adelaja, Yemi A., Adewetan, Gbadebo, Adlou, Syed, Ahmed, Khatija, Akhalwaya, Yasmeen, Akhalwaya, Saajida, Alcock, Andrew, Ali, Aabidah, Allen, Elizabeth R., Allen, Lauren, Almeida, Thamires C. D. S. C, Alves, Mariana P.S., Amorim, Fabio, Andritsou, Foteini, Anslow, Rachel, Appleby, Matthew, Arbe-Barnes, Edward H., Ariaans, Mark P., Arns, Beatriz, Arruda, Laiana, Azi, Paula, Azi, Lorena, Babbage, Gavin, Bailey, Catherine, Baker, Kenneth F., Baker, Megan, Baker, Natalie, Baker, Philip, Baldwin, Lisa, Baleanu, Ioana, Bandeira, Danieli, Bara, Anna, Barbosa, Marcella A.S., Barker, Debbie, Barlow, Gavin D., Barnes, Eleanor, Barr, Andrew S., Barrett, Jordan R., Barrett, Jessica, Bates, Louise, Batten, Alexander, Beadon, Kirsten, Beales, Emily, Beckley, Rebecca, Belij-Rammerstorfer, Sandra, Bell, Jonathan, Bellamy, Duncan, Bellei, Nancy, Belton, Sue, Berg, Adam, Bermejo, Laura, Berrie, Eleanor, Berry, Lisa, Berzenyi, Daniella, Beveridge, Amy, Bewley, Kevin R., Bexhell, Helen, Bhikha, Sutika, Bhorat, Asad E., Bhorat, Zaheda E., Bijker, Else, Birch, Geeta, Birch, Sarah, Bird, Adam, Bird, Olivia, Bisnauthsing, Karen, Bittaye, Mustapha, Blackstone, Katherine, Blackwell, Luke, Bletchly, Heather, Blundell, Caitlin L., Blundell, Susannah R., Bodalia, Pritesh, Boettger, Bruno C., Bolam, Emma, Boland, Elena, Bormans, Daan, Borthwick, Nicola, Bowring, Francesca, Boyd, Amy, Bradley, Penny, Brenner, Tanja, Brown, Phillip, Brown, Claire, Brown-O'Sullivan, Charlie, Bruce, Scott, Brunt, Emily, Buchan, Ruaridh, Budd, William, Bulbulia, Yusuf A., Bull, Melanie, Burbage, Jamie, Burhan, Hassan, Burn, Aileen, Buttigieg, Karen R., Byard, Nicholas, Cabera Puig, Ingrid, Calderon, Gloria, Calvert, Anna, Camara, Susana, Cao, Michelangelo, Cappuccini, Federica, Cardoso, João R., Carr, Melanie, Carroll, Miles W., Carson-Stevens, Andrew, Carvalho, Yasmin de M., Carvalho, José A.M., Casey, Helen R., Cashen, Paul, Castro, Thais, Castro, Lucia Carratala, Cathie, Katrina, Cavey, Ana, Cerbino-Neto, José, Chadwick, Jim, Chapman, David, Charlton, Sue, Chelysheva, Irina, Chester, Oliver, Chita, Sunder, Cho, Jee-Sun, Cifuentes, Liliana, Clark, Elizabeth, Clark, Matthew, Clarke, Andrea, Clutterbuck, Elizabeth A., Collins, Sarah L.K., Conlon, Christopher P., Connarty, Sean, Coombes, Naomi, Cooper, Cushla, Cooper, Rachel, Cornelissen, Lynne, Corrah, Tumena, Cosgrove, Catherine, Cox, Tony, Crocker, Wendy E.M., Crosbie, Sarah, Cullen, Lorraine, Cullen, Dan, Cunha, Debora R.M.F., Cunningham, Christina, Cuthbertson, Fiona C., Da Guarda, Suzete N. Farias, da Silva, Larissa P., Damratoski, Brad E., Danos, Zsofia, Dantas, Maria T.D.C., Darroch, Paula, Datoo, Mehreen S., Datta, Chandrabali, Davids, Malika, Davies, Sarah L., Davies, Hannah, Davis, Elizabeth, Davis, Judith, Davis, John, De Nobrega, Maristela M.D., De Oliveira Kalid, Lis Moreno, Dearlove, David, Demissie, Tesfaye, Desai, Amisha, Di Marco, Stefania, Di Maso, Claudio, Dinelli, Maria I.S., Dinesh, Tanya, Docksey, Claire, Dold, Christina, Dong, Tao, Donnellan, Francesca R., Dos Santos, Tannyth, dos Santos, Thainá G., Dos Santos, Erika Pachecho, Douglas, Naomi, Downing, Charlotte, Drake, Jonathan, Drake-Brockman, Rachael, Driver, Kimberley, Drury, Ruth, Dunachie, Susanna J., Durham, Benjamin S., Dutra, Lidiana, Easom, Nicholas J.W., van Eck, Samual, Edwards, Mandy, Edwards, Nick J., El Muhanna, Omar M., Elias, Sean C., Elmore, Mike, English, Marcus, Esmail, Alisgair, Essack, Yakub Moosa, Farmer, Eoghan, Farooq, Mutjaba, Farrar, Madi, Farrugia, Leonard, Faulkner, Beverley, Fedosyuk, Sofiya, Felle, Sally, Feng, Shuo, Ferreira Da Silva, Carla, Field, Samantha, Fisher, Richard, Flaxman, Amy, Fletcher, James, Fofie, Hazel, Fok, Henry, Ford, Karen J., Fowler, Jamie, Fraiman, Pedro H.A., Francis, Emma, Franco, Marilia M., Frater, John, Freire, Marilúcia S.M., Fry, Samantha H., Fudge, Sabrina, Furze, Julie, Fuskova, Michelle, Galian-Rubio, Pablo, Galiza, Eva, Garlant, Harriet, Gavrila, Madita, Geddes, Ailsa, Gibbons, Karyna A., Gilbride, Ciaran, Gill, Hardeep, Glynn, Sharon, Godwin, Kerry, Gokani, Karishma, Goldoni, Ursula Carvalho, Goncalves, Maria, Gonzalez, Isabela G.S., Goodwin, Jayne, Goondiwala, Amina, Gordon-Quayle, Katherine, Gorini, Giacomo, Grab, Janet, Gracie, Lara, Greenland, Melanie, Greenwood, Nicola, Greffrath, Johann, Groenewald, Marisa M., Grossi, Leonardo, Gupta, Gaurav, Hackett, Mark, Hallis, Bassam, Hamaluba, Mainga, Hamilton, Elizabeth, Hamlyn, Joseph, Hammersley, Daniel, Hanrath, Aidan T., Hanumunthadu, Brama, Harris, Stephanie A., Harris, Clair, Harris, Tara, Harrison, Thomas D., Harrison, Daisy, Hart, Thomas C., Hartnell, Birgit, Hassan, Shadin, Haughney, John, Hawkins, Sophia, Hay, Jodie, Head, Ian, Henry, John, Hermosin Herrera, Macarena, Hettle, David B., Hill, Jennifer, Hodges, Gina, Horne, Elizea, Hou, Mimi M., Houlihan, Catherine, Howe, Elizabeth, Howell, Nicola, Humphreys, Jonathan, Humphries, Holly E., Hurley, Katrina, Huson, Claire, Hyder-Wright, Angela, Hyams, Catherine, Ikram, Sabina, Ishwarbhai, Alka, Ivan, Monica, Iveson, Poppy, Iyer, Vidyashankara, Jackson, Frederic, De Jager, Jeanne, Jaumdally, Shameem, Jeffers, Helen, Jesudason, Natasha, Jones, Bryony, Jones, Kathryn, Jones, Elizabeth, Jones, Christopher, Jorge, Marianna Rocha, Jose, Aylin, Joshi, Amar, Júnior, Eduardo A.M.S., Kadziola, Joanne, Kailath, Reshma, Kana, Faeeza, Karampatsas, Konstantinos, Kasanyinga, Mwila, Keen, Jade, Kelly, Elizabeth J., Kelly, Dearbhla M., Kelly, Debbie, Kelly, Sarah, Kerr, David, Kfouri, Renato de Ávila, Khan, Liaquat, Khozoee, Baktash, Kidd, Sarah, Killen, Annabel, Kinch, Jasmin, Kinch, Patrick, King, Lloyd D.W., King, Thomas B., Kingham, Lucy, Klenerman, Paul, Knapper, Francesca, Knight, Julian C., Knott, Daniel, Koleva, Stanislava, Lang, Matilda, Lang, Gail, Larkworthy, Colin W., Larwood, Jessica P.J., Law, Rebecca, Lazarus, Erica M., Leach, Amanda, Lees, Emily A., Lemm, Nana-Marie, Lessa, Alvaro, Leung, Stephanie, Li, Yuanyuan, Lias, Amelia M., Liatsikos, Kostas, Linder, Aline, Lipworth, Samuel, Liu, Shuchang, Liu, Xinxue, Lloyd, Adam, Lloyd, Stephanie, Loew, Lisa, Lopez Ramon, Raquel, Lora, Leandro, Lowthorpe, Vicki, Luz, Kleber, MacDonald, Jonathan C., MacGregor, Gordon, Madhavan, Meera, Mainwaring, David O., Makambwa, Edson, Makinson, Rebecca, Malahleha, Mookho, Malamatsho, Ross, Mallett, Garry, Mansatta, Kushal, Maoko, Takalani, Mapetla, Katlego, Marchevsky, Natalie G., Marinou, Spyridoula, Marlow, Emma, Marques, Gabriela N., Marriott, Paula, Marshall, Richard P., Marshall, Julia L., Martins, Flávia J., Masenya, Masebole, Masilela, Mduduzi, Masters, Shauna K., Mathew, Moncy, Matlebjane, Hosea, Matshidiso, Kedidimetse, Mazur, Olga, Mazzella, Andrea, McCaughan, Hugh, McEwan, Joanne, McGlashan, Joanna, McInroy, Lorna, McIntyre, Zoe, McLenaghan, Daniela, McRobert, Nicky, McSwiggan, Steve, Megson, Clare, Mehdipour, Savviz, Meijs, Wilma, Mendonça, Renata N.Á., Mentzer, Alexander J., Mirtorabi, Neginsadat, Mitton, Celia, Mnyakeni, Sibusiso, Moghaddas, Fiona, Molapo, Kgaogelo, Moloi, Mapule, Moore, Maria, Moraes-Pinto, M. Isabel, Moran, Marni, Morey, Ella, Morgans, Róisín, Morris, Susan, Morris, Sheila, Morris, Helen C., Morselli, Franca, Morshead, Gertraud, Morter, Richard, Mottal, Lynelle, Moultrie, Andrew, Moya, Nathifa, Mpelembue, Mushiya, Msomi, Sibekezelo, Mugodi, Yvonne, Mukhopadhyay, Ekta, Muller, Jilly, Munro, Alasdair, Munro, Claire, Murphy, Sarah, Mweu, Philomena, Myasaki, Celia Hatsuko, Naik, Gurudutt, Naker, Kush, Nastouli, Eleni, Nazir, Abida, Ndlovu, Bongani, Neffa, Fabio, Njenga, Cecilia, Noal, Helena, Noé, Andrés, Novaes, Gabrielle, Nugent, Fay L., Nunes, Géssika, O'Brien, Katie, O'Connor, Daniel, Odam, Miranda, Oelofse, Suzette, Oguti, Blanche, Olchawski, Victoria, Oldfield, Neil J., Oliveira, Marianne G., Oliveira, Catarina, Oosthuizen, Angela, O'Reilly, Paula, Osborne, Piper, Owen, David R.J., Owen, Lydia, Owens, Daniel, Owino, Nelly, Pacurar, Mihaela, Paiva, Brenda V.B., Palhares, Edna M.F., Palmer, Susan, Parkinson, Sivapriyai, Parracho, Helena M.R.T., Parsons, Karen, Patel, Dipak, Patel, Bhumika, Patel, Faeezah, Patel, Kelly, Patrick-Smith, Maia, Payne, Ruth O., Peng, Yanchun, Penn, Elizabeth J., Pennington, Anna, Peralta Alvarez, Marco Polo, Perring, James, Perry, Nicola, Perumal, Rubeshan, Petkar, Sahir, Philip, Tricia, Phillips, Daniel J., Phillips, Jennifer, Phohu, Mary Kgomotso, Pickup, Lorinda, Pieterse, Sonja, Piper, Jo, Pipini, Dimitra, Plank, Mary, Du Plessis, Joan, Pollard, Samuel, Pooley, Jennifer, Pooran, Anil, Poulton, Ian, Powers, Claire, Presa, Fernando B., Price, David A., Price, Vivien, Primeira, Marcelo, Proud, Pamela C., Provstgaard-Morys, Samuel, Pueschel, Sophie, Pulido, David, Quaid, Sheena, Rabara, Ria, Radford, Alexandra, Radia, Kajal, Rajapaska, Durga, Rajeswaran, Thurkka, Ramos, Alberto San Francisco, Ramos Lopez, Fernando, Rampling, Tommy, Rand, Jade, Ratcliffe, Helen, Rawlinson, Tom, Rea, David, Rees, Byron, Reiné, Jesús, Resuello-Dauti, Mila, Reyes Pabon, Emilia, Ribiero, Carla M., Ricamara, Marivic, Richter, Alex, Ritchie, Neil, Ritchie, Adam J., Robbins, Alexander J., Roberts, Hannah, Robinson, Ryan E., Robinson, Hannah, Rocchetti, Talita T., Rocha, Beatriz Pinho, Roche, Sophie, Rollier, Christine, Rose, Louisa, Ross Russell, Amy L., Rossouw, Lindie, Royal, Simon, Rudiansyah, Indra, Ruiz, Sarah, Saich, Stephen, Sala, Claudia, Sale, Jessica, Salman, Ahmed M., Salvador, Natalia, Salvador, Stephannie, Sampaio, Milla, Samson, Annette D., Sanchez-Gonzalez, Amada, Sanders, Helen, Sanders, Katherine, Santos, Erika, Santos Guerra, Mayara F.S., Satti, Iman, Saunders, Jack E., Saunders, Caroline, Sayed, Aakifah, Schim van der Loeff, Ina, Schmid, Annina B., Schofield, Ella, Screaton, Gavin, Seddiqi, Samiullah, Segireddy, Rameswara R., Senger, Roberta, Serrano, Sonia, Shah, Rajiv, Shaik, Imam, Sharpe, Hannah E., Sharrocks, Katherine, Shaw, Robert, Shea, Adam, Shepherd, Amy, Shepherd, James G., Shiham, Farah, Sidhom, Emad, Silk, Sarah E., da Silva Moraes, Antonio Carlos, Silva-Junior, Gilberto, Silva-Reyes, Laura, Silveira, Anderson D., Silveira, Mariana B.V., Sinha, Jaisi, Skelly, Donal T., Smith, Daniel C., Smith, Nick, Smith, Holly E., Smith, David J., Smith, Catherine C., Soares, Airanuédida, Soares, Tiago, Solórzano, Carla, Sorio, Guilherme L., Sorley, Kim, Sosa-Rodriguez, Tiffany, Souza, Cinthia M.C.D.L., Souza, Bruno S.D.F., Souza, Alessandra R., Spencer, Alexandra J., Spina, Fernanda, Spoors, Louise, Stafford, Lizzie, Stamford, Imogen, Starinskij, Igor, Stein, Ricardo, Steven, Jill, Stockdale, Lisa, Stockwell, Lisa V., Strickland, Louise H., Stuart, Arabella C., Sturdy, Ann, Sutton, Natalina, Szigeti, Anna, Tahiri-Alaoui, Abdessamad, Tanner, Rachel, Taoushanis, Carol, Tarr, Alexander W., Taylor, Keja, Taylor, Ursula, Taylor, Iona Jennifer, Taylor, Justin, te Water Naude, Rebecca, Themistocleous, Yrene, Themistocleous, Andreas, Thomas, Merin, Thomas, Kelly, Thomas, Tonia M., Thombrayil, Asha, Thompson, Fawziyah, Thompson, Amber, Thompson, Kevin, Thompson, Ameeka, Thomson, Julia, Thornton-Jones, Viv, Tighe, Patrick J., Tinoco, Lygia Accioly, Tiongson, Gerlynn, Tladinyane, Bonolo, Tomasicchio, Michele, Tomic, Adriana, Tonks, Susan, Towner, James, Tran, Nguyen, Tree, Julia, Trillana, Gerry, Trinham, Charlotte, Trivett, Rose, Truby, Adam, Tsheko, Betty Lebogang, Turabi, Aadil, Turner, Richard, Turner, Cheryl, Ulaszewska, Marta, Underwood, Benjamin R., Varughese, Rachel, Verbart, Dennis, Verheul, Marije, Vichos, Iason, Vieira, Taiane, Waddington, Claire S., Walker, Laura, Wallis, Erica, Wand, Matthew, Warbick, Deborah, Wardell, Theresa, Warimwe, George, Warren, Sarah C., Watkins, Bridget, Watson, Ekaterina, Webb, Stewart, Webb-Bridges, Alice, Webster, Angela, Welch, Jessica, Wells, Jeanette, West, Alison, White, Caroline, White, Rachel, Williams, Paul, Williams, Rachel L., Winslow, Rebecca, Woodyer, Mark, Worth, Andrew T., Wright, Danny, Wroblewska, Marzena, Yao, Andy, Zimmer, Rafael, Zizi, Dalila, Zuidewind, Peter, Voysey, Merryn, Clemens, Sue Ann Costa, Madhi, Shabir A, Weckx, Lily Y, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian, Baillie, Vicky L, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Collins, Andrea M, Colin-Jones, Rachel, Cutland, Clare L, Darton, Thomas C, Dheda, Keertan, Duncan, Christopher J A, Emary, Katherine R W, Ewer, Katie J, Fairlie, Lee, Faust, Saul N, Ferreira, Daniela M, Finn, Adam, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Heath, Paul T, Hill, Catherine, Hill, Helen, Hirsch, Ian, Hodgson, Susanne H C, Izu, Alane, Jackson, Susan, Jenkin, Daniel, Joe, Carina C D, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Lawrie, Alison M, Lelliott, Alice, Libri, Vincenzo, Lillie, Patrick J, Mallory, Raburn, Mendes, Ana V A, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair, Morrison, Hazel, Mujadidi, Yama F, Nana, Anusha, O’Reilly, Peter J, Padayachee, Sherman D, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Rhead, Sarah, Schwarzbold, Alexandre V, Singh, Nisha, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Tarrant, Richard, Thomson, Emma C, Török, M Estée, Toshner, Mark, Turner, David P J, Vekemans, Johan, Villafana, Tonya L, Watson, Marion E E, Williams, Christopher J, Douglas, Alexander D, Hill, Adrian V S, Lambe, Teresa, Gilbert, Sarah C, and Pollard, Andrew J

Published
2021
Full Text
View/download PDF

11. Comparing Conservative and Early Surgical Treatments for Pyogenic Spondylodiscitis: An International Propensity-Score-Matched Retrospective Outcome Analysis

Author

Neuhoff, Jonathan, primary, Kramer, Andreas, additional, Thavarajasingam, Santhosh, additional, Sutherland, Rebecca K., additional, McCaughan, Hugh, additional, Joerger, Ann-Kathrin, additional, Wostrack, Maria, additional, Lyell, Barrie, additional, Berkulian, Olga, additional, Ponniah, Hariharan Subbiah, additional, Ramsay, Daniele, additional, Meyer, Bernhard, additional, Kandziora, Frank, additional, Shiban, Ehab, additional, Davies, Benjamin, additional, Demetriades, Andreas, additional, and Ringel, Florian, additional

Published
2023
Full Text
View/download PDF

12. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Author

Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Yin, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth, Collins, Andrea M, Cutland, Clare, Darton, Thomas, Dheda, Keertan, Douglas, Alexander D, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie, Marshall, Richard P, Mendes, Ana Verena Almeida, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Nana, Anusha, Payadachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, Mili Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew, and Group, Oxford COVID Vaccine Trial

Published
2022
Full Text
View/download PDF

13. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Author

Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian John, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth, Collins, Andrea M, Cox, Tony, Darton, Thomas, Dold, Christina, Douglas, Alexander D, Duncan, Christopher JA, Ewer, Katie, Flaxman, Amy, Faust, Saul N, Ferreira, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, Pollard, Andrew, Consortium, COVID-19 Genomics UK COG-UK, and Group, Oxford COVID Vaccine Trial

Published
2022
Full Text
View/download PDF

14. T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire

Author

Swanson, Phillip A., Padilla, Marcelino, Hoyland, Wesley, McGlinchey, Kelly, Fields, Paul A., Bibi, Sagida, Faust, Saul N., McDermott, Adrian B., Lambe, Teresa, Pollard, Andrew J., Durham, Nicholas M., Kelly, Elizabeth J., Adlou, Syed, Aley, Parvinder K., Angus, Brian, Anslow, Rachel, Baker, Philip, Bansal, Himanshu, Beveridge, Amy, Bridges-Webb, Alice, Ching, Steven, Cicconi, Paola, Clutterbuck, Elizabeth A., Collins, Andrea M., Darton, Thomas C., Demissie, Tesfaye, Dinesh, Tanya, Douglas, Alexander D., Duncan, Christopher J. A., Ewer, Katie J., Felle, Sally, Finn, Adam, Folegatti, Pedro M., Fuskova, Michelle, Gilbert, Sarah C., Goodman, Anna, Green, Christopher A., Harbolick, Elizabeth, Hart, Thomas C., Hayes, Susana, Hill, Adrian V. S., Jenkin, Daniel, Jepson, Brett M., Kasanyinga, Mwila, Kerridge, Simon, Libri, Vincenzo, Lillie, Patrick J., McGregor, Alastair C., Minassian, Angela M., Mujadidi, Yama F., Pilataxi, Fernanda, Plested, Emma, Provstgaard-Morys, Samuel, Ramasamy, Maheshi, Robinson, Hannah, Sanders, Katherine, Smith, Andrew, Snape, Matthew D., Song, Rinn, Sutherland, Rebecca K., Thomson, Emma C., Toshner, Mark, Turner, David P. J., Voysey, Merryn, and Williams, Christopher J.

Subjects
COVID-19 Vaccines, SARS-CoV-2, Immunogenicity, T cell, Vaccination, T-cell receptor, Receptors, Antigen, T-Cell, COVID-19, Biology, Peripheral blood mononuclear cell, Article, T cell mediated immunity, medicine.anatomical_structure, ChAdOx1 nCoV-19, Spike Glycoprotein, Coronavirus, Immunology, medicine, Humans, Receptor, CD8
Abstract

AZD1222 (ChAdOx1 nCoV-19), a replication-deficient simian adenovirus-vectored vaccine, has demonstrated safety, efficacy, and immunogenicity against coronavirus disease 2019 (COVID-19) in clinical trials and real-world studies. We characterized CD4+ and CD8+ T-cell responses induced by AZD1222 vaccination in peripheral blood mononuclear cells (PBMCs) from 280 unique vaccine recipients aged 18–85 years who enrolled in the phase 2/3 COV002 trial. Total spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses were significantly increased in AZD1222-vaccinated adults of all ages following two doses of AZD1222. CD4+ Th2 responses following AZD1222 vaccination were not detected. Furthermore, AZD1222-specific Th1 and CD8+ T cells both displayed a high degree of polyfunctionality in all adult age groups. T-cell receptor (TCR) β sequences from vaccinated participants mapped against TCR sequences known to react to SARS-CoV-2 revealed substantial breadth and depth across the SARS-CoV-2 spike protein for the AZD1222-induced CD4+ and CD8+ T-cell responses. Overall, AZD1222 vaccination induced a robust, polyfunctional Th1-dominated T-cell response, with broad CD4+ and CD8+ T-cell coverage across the SARS-CoV-2 spike protein.One Sentence SummaryPolyfunctional CD4+ and CD8+ T-cell responses are elicited against the SARS-CoV-2 spike protein following vaccination with AZD1222

Published
2021
Full Text
View/download PDF

15. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B.1.1.7), an exploratory analysis of a randomised controlled trial

Author

Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth A, Collins, Andrea M, Cox, Tony, Darton, Thomas C, Dold, Christina, Douglas, Alexander D, Duncan, Christopher JA, Ewer, Katie J, Flaxman, Amy L, Faust, Saul N, Ferreir, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie G, Minassian, Angela M, McGregor, Alastair C, Mujadidi, Yama F, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, Pollard, Andrew J, Consortium, The COVID-19 Genomics UK, Project, The AMPHEUS, Group, The Oxford COVID-19 Vaccine Trial, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository

Abstract

A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the United Kingdom from November 2020. Here we report efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19, against this variant., COVID-19 Genomics UK is supported by funding from the Medical Research Council, part of UK Research and Innovation, the NIHR, and Genome Research, operating as the Wellcome Sanger Institute.

Published
2021
Full Text
View/download PDF

16. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Author

Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Y, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian, Baillie, Vicky L, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth A, Collins, Andrea M, Cutland, Clare L, Darton, Thomas C, Dheda, Keertan, Dold, Christina, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie J, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Joe, Carina CD, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie G, Marshall, Richard P, Mendes, Ana VA, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair, Mujadidi, Yama F, Nana, Anusha, Padayachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Ritchie, Adam J, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, M Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Douglas, Alexander D, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew J, and Oxford COVID Vaccine Trial Group

Abstract

Background\ud The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses. In addition, we show the immunogenicity and protection afforded by the first dose, before a booster dose has been offered.MethodsWe present data from three single-blind randomised controlled trials-one phase 1/2 study in the UK (COV001), one phase 2/3 study in the UK (COV002), and a phase 3 study in Brazil (COV003)-and one double-blind phase 1/2 study in South Africa (COV005). As previously described, individuals 18 years and older were randomly assigned 1:1 to receive two standard doses of ChAdOx1 nCoV-19 (5 × 1010 viral particles) or a control vaccine or saline placebo. In the UK trial, a subset of participants received a lower dose (2·2 × 1010 viral particles) of the ChAdOx1 nCoV-19 for the first dose. The primary outcome was virologically confirmed symptomatic COVID-19 disease, defined as a nucleic acid amplification test (NAAT)-positive swab combined with at least one qualifying symptom (fever ≥37·8°C, cough, shortness of breath, or anosmia or ageusia) more than 14 days after the second dose. Secondary efficacy analyses included cases occuring at least 22 days after the first dose. Antibody responses measured by immunoassay and by pseudovirus neutralisation were exploratory outcomes. All cases of COVID-19 with a NAAT-positive swab were adjudicated for inclusion in the analysis by a masked independent endpoint review committee. The primary analysis included all participants who were SARS-CoV-2 N protein seronegative at baseline, had had at least 14 days of follow-up after the second dose, and had no evidence of previous SARS-CoV-2 infection from NAAT swabs. Safety was assessed in all participants who received at least one dose. The four trials are registered at ISRCTN89951424 (COV003) and ClinicalTrials.gov, NCT04324606 (COV001), NCT04400838 (COV002), and NCT04444674 (COV005).FindingsBetween April 23 and Dec 6, 2020, 24 422 participants were recruited and vaccinated across the four studies, of whom 17 178 were included in the primary analysis (8597 receiving ChAdOx1 nCoV-19 and 8581 receiving control vaccine). The data cutoff for these analyses was Dec 7, 2020. 332 NAAT-positive infections met the primary endpoint of symptomatic infection more than 14 days after the second dose. Overall vaccine efficacy more than 14 days after the second dose was 66·7% (95% CI 57·4-74·0), with 84 (1·0%) cases in the 8597 participants in the ChAdOx1 nCoV-19 group and 248 (2·9%) in the 8581 participants in the control group. There were no hospital admissions for COVID-19 in the ChAdOx1 nCoV-19 group after the initial 21-day exclusion period, and 15 in the control group. 108 (0·9%) of 12 282 participants in the ChAdOx1 nCoV-19 group and 127 (1·1%) of 11 962 participants in the control group had serious adverse events. There were seven deaths considered unrelated to vaccination (two in the ChAdOx1 nCov-19 group and five in the control group), including one COVID-19-related death in one participant in the control group. Exploratory analyses showed that vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 after vaccination was 76·0% (59·3-85·9). Our modelling analysis indicated that protection did not wane during this initial 3-month period. Similarly, antibody levels were maintained during this period with minimal waning by day 90 (geometric mean ratio [GMR] 0·66 [95% CI 0·59-0·74]). In the participants who received two standard doses, after the second dose, efficacy was higher in those with a longer prime-boost interval (vaccine efficacy 81·3% [95% CI 60·3-91·2] at ≥12 weeks) than in those with a short interval (vaccine efficacy 55·1% [33·0-69·9] at InterpretationThe results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in exploratory analyses. A 3-month dose interval might have advantages over a programme with a short dose interval for roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when supplies are scarce, while also improving protection after receiving a second dose.FundingUK Research and Innovation, National Institutes of Health Research (NIHR), The Coalition for Epidemic Preparedness Innovations, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D'Or, the Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

Published
2021

18. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Author

Voysey, Merryn, Clemens, Sue Ann Costa, Madhi, Shabir A., Weckx, Lily Y., Folegatti, Pedro M., Aley, Parvinder K., Angus, Brian, Baillie, Vicky L., Barnabas, Shaun L., Bhorat, Qasim E., Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Collins, Andrea M., Colin-Jones, Rachel, Cutland, Clare L., Darton, Thomas C., Dheda, Keertan, Duncan, Christopher J. A., Emary, Katherine R. W., Ewer, Katie J., Fairlie, Lee, Faust, Saul N., Feng, Shuo, Ferreira, Daniela M., Finn, Adam, Goodman, Anna L., Green, Catherine M., Green, Christopher A., Heath, Paul T., Hill, Catherine, Hill, Helen, Hirsch, Ian, Hodgson, Susanne H. C., Izu, Alane, Jackson, Susan, Jenkin, Daniel, Joe, Carina C. D., Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Lawrie, Alison M., Lelliott, Alice, Libri, Vincenzo, Lillie, Patrick J., Mallory, Raburn, Mendes, Ana V. A., Milan, Eveline P., Minassian, Angela M., McGregor, Alastair, Morrison, Hazel, Mujadidi, Yama F., Nana, Anusha, O'Reilly, Peter J., Padayachee, Sherman D., Pittella, Ana, Plested, Emma, Pollock, Katrina M., Ramasamy, Maheshi N., Rhead, Sarah, Schwarzbold, Alexandre V., Singh, Nisha, Smith, Andrew, Song, Rinn, Snape, Matthew D., Sprinz, Eduardo, Sutherland, Rebecca K., Tarrant, Richard, Thomson, Emma C., Török, Mark and Turner, Sorio, Guilherme L., Sorley, Kim, Sosa-Rodriguez, Tiffany, Souza, Cinthia M.C.D.L., Souza, Bruno S.D.F., Souza, Alessandra R., Spencer, Alexandra J., Spina, Fernanda, Spoors, Louise, Stafford, Lizzie, Stamford, Imogen, Starinskij, Igor, Stein, Ricardo, Steven, Jill, Stockdale, Lisa, Stockwell, Lisa V., Strickland, Louise H., Stuart, Arabella C., Sturdy, Ann, Sutton, Natalina, Szigeti, Anna, Tahiri-Alaoui, Abdessamad, Tanner, Rachel, Taoushanis, Carol, Tarr, Alexander W., Taylor, Keja, Taylor, Ursula, Taylor, Iona Jennifer, Taylor, Justin, te Water Naude, Rebecca, Themistocleous, Yrene, Themistocleous, Andreas, Thomas, Merin, Thomas, Kelly, Thomas, Tonia M., Thombrayil, Asha, Thompson, Fawziyah, Thompson, Amber, Thompson, Kevin, Thompson, Ameeka, Thomson, Julia, Thornton-Jones, Viv, Tighe, Patrick J., Tinoco, Lygia Accioly, Tiongson, Gerlynn, Tladinyane, Bonolo, Tomasicchio, Michele, Tomic, Adriana, Tonks, Susan, Tran, Nguyen, Tree, Julia, Trillana, Gerry, Trinham, Charlotte, Trivett, Rose, Truby, Adam, Tsheko, Betty Lebogang, Turabi, Aadil, Turner, Richard, Turner, Cheryl, Ulaszewska, Marta, Underwood, Benjamin R., Varughese, Rachel, Verbart, Dennis, Verheul, Marije, Vichos, Iason, Vieira, Taiane, Waddington, Claire S., Walker, Laura, Wallis, Erica, Wand, Matthew, Warbick, Deborah, Wardell, Theresa, Warimwe, George, Warren, Sarah C., Watkins, Bridget, Watson, Ekaterina, Webb, Stewart, Webb-Bridges, Alice, Webster, Angela, Welch, Jessica, Wells, Jeanette, West, Alison, White, Caroline, White, Rachel, Williams, Paul, Williams, Rachel L., Winslow, Rebecca, Woodyer, Mark, Worth, Andrew T., Wright, Danny, Wroblewska, Marzena, Yao, Andy, Zimmer, Rafael, Zizi, Dalila, and Zuidewind, Peter

Abstract

Background: \ud A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials.\ud \ud Methods: \ud This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674.\ud \ud Findings: \ud Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation.\ud \ud Interpretation: \ud ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.\ud \ud Funding: \ud UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D’Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

Published
2021

19. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Author

Emary, Katherine R. W., primary, Golubchik, Tanya, additional, Aley, Parvinder K., additional, Ariani, Cristina V., additional, Angus, Brian John, additional, Bibi, Sagida, additional, Blane, Beth, additional, Bonsall, David, additional, Cicconi, Paola, additional, Charlton, Sue, additional, Clutterbuck, Elizabeth, additional, Collins, Andrea M., additional, Cox, Tony, additional, Darton, Thomas, additional, Dold, Christina, additional, Douglas, Alexander D., additional, Duncan, Christopher J. A., additional, Ewer, Katie, additional, Flaxman, Amy, additional, Faust, Saul N., additional, Ferreira, Daniela M., additional, Feng, Shuo, additional, Finn, Adam, additional, Folegatti, Pedro M., additional, Fuskova, Michelle, additional, Galiza, Eva, additional, Goodman, Anna L., additional, Green, Catherine M., additional, Green, Christopher A., additional, Greenland, Melanie, additional, Hallis, Bassam, additional, Heath, Paul T., additional, Hay, Jodie, additional, Hill, Helen C., additional, Jenkin, Daniel, additional, Kerridge, Simon, additional, Lazarus, Rajeka, additional, Libri, Vincenzo, additional, Lillie, Patrick J., additional, Ludden, Catherine, additional, Marchevsky, Natalie G., additional, Minassian, Angela M., additional, McGregor, Alastair C., additional, Farooq Mujadidi, Yama, additional, Phillips, Daniel J., additional, Plested, Emma, additional, Pollock, Katrina M., additional, Robinson, Hannah, additional, Smith, Andrew, additional, Song, Rinn, additional, Snape, Matthew D., additional, Sutherland, Rebecca K., additional, Thomson, Emma C., additional, Toshner, Mark, additional, Turner, David P. J., additional, Vekemans, Johan, additional, Villafana, Tonya L., additional, Williams, Christopher J., additional, Hill, Adrian V. S., additional, Lambe, Teresa, additional, Gilbert, Sarah C., additional, Voysey, Merryn, additional, Ramasamy, Maheshi N., additional, Pollard, Andrew, additional, and Group, Oxford COVID Vaccine Trial, additional

Published
2021
Full Text
View/download PDF

20. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Author

Voysey, Merryn, primary, Costa Clemens, Sue Ann, additional, Madhi, Shabir A., additional, Weckx, Lily Yin, additional, Folegatti, Pedro M., additional, Aley, Parvinder K., additional, Angus, Brian John, additional, Baillie, Vicky, additional, Barnabas, Shaun L., additional, Bhorat, Qasim E., additional, Bibi, Sagida, additional, Briner, Carmen, additional, Cicconi, Paola, additional, Clutterbuck, Elizabeth, additional, Collins, Andrea M., additional, Cutland, Clare, additional, Darton, Thomas, additional, Dheda, Keertan, additional, Douglas, Alexander D., additional, Duncan, Christopher J. A., additional, Emary, Katherine R. W., additional, Ewer, Katie, additional, Flaxman, Amy, additional, Fairlie, Lee, additional, Faust, Saul N., additional, Feng, Shuo, additional, Ferreira, Daniela M., additional, Finn, Adam, additional, Galiza, Eva, additional, Goodman, Anna L., additional, Green, Catherine M., additional, Green, Christopher A., additional, Greenland, Melanie, additional, Hill, Catherine, additional, Hill, Helen C., additional, Hirsch, Ian, additional, Izu, Alane, additional, Jenkin, Daniel, additional, Kerridge, Simon, additional, Koen, Anthonet, additional, Kwatra, Gaurav, additional, Lazarus, Rajeka, additional, Libri, Vincenzo, additional, Lillie, Patrick J., additional, Marchevsky, Natalie G., additional, Marshall, Richard P., additional, Mendes, Ana Verena Almeida, additional, Milan, Eveline P., additional, Minassian, Angela M., additional, McGregor, Alastair C., additional, Farooq Mujadidi, Yama, additional, Nana, Anusha, additional, Payadachee, Sherman D., additional, Phillips, Daniel J., additional, Pittella, Ana, additional, Plested, Emma, additional, Pollock, Katrina M., additional, Ramasamy, Maheshi N., additional, Robinson, Hannah, additional, Schwarzbold, Alexandre V., additional, Smith, Andrew, additional, Song, Rinn, additional, Snape, Matthew D., additional, Sprinz, Eduardo, additional, Sutherland, Rebecca K., additional, Thomson, Emma C., additional, Torok, Mili, additional, Toshner, Mark, additional, Turner, David P. J., additional, Vekemans, Johan, additional, Villafana, Tonya L., additional, White, Thomas, additional, Williams, Christopher J., additional, Hill, Adrian V. S., additional, Lambe, Teresa, additional, Gilbert, Sarah C., additional, Pollard, Andrew, additional, and Group, Oxford COVID Vaccine Trial, additional

Published
2021
Full Text
View/download PDF

22. Oral versus Intravenous Antibiotics for Bone and Joint Infection

Author

Li, Ho-Kwong, primary, Rombach, Ines, additional, Zambellas, Rhea, additional, Walker, A. Sarah, additional, McNally, Martin A., additional, Atkins, Bridget L., additional, Lipsky, Benjamin A., additional, Hughes, Harriet C., additional, Bose, Deepa, additional, Kümin, Michelle, additional, Scarborough, Claire, additional, Matthews, Philippa C., additional, Brent, Andrew J., additional, Lomas, Jose, additional, Gundle, Roger, additional, Rogers, Mark, additional, Taylor, Adrian, additional, Angus, Brian, additional, Byren, Ivor, additional, Berendt, Anthony R., additional, Warren, Simon, additional, Fitzgerald, Fiona E., additional, Mack, Damien J.F., additional, Hopkins, Susan, additional, Folb, Jonathan, additional, Reynolds, Helen E., additional, Moore, Elinor, additional, Marshall, Jocelyn, additional, Jenkins, Neil, additional, Moran, Christopher E., additional, Woodhouse, Andrew F., additional, Stafford, Samantha, additional, Seaton, R. Andrew, additional, Vallance, Claire, additional, Hemsley, Carolyn J., additional, Bisnauthsing, Karen, additional, Sandoe, Jonathan A.T., additional, Aggarwal, Ila, additional, Ellis, Simon C., additional, Bunn, Deborah J., additional, Sutherland, Rebecca K., additional, Barlow, Gavin, additional, Cooper, Cushla, additional, Geue, Claudia, additional, McMeekin, Nicola, additional, Briggs, Andrew H., additional, Sendi, Parham, additional, Khatamzas, Elham, additional, Wangrangsimakul, Tri, additional, Wong, T.H. Nicholas, additional, Barrett, Lucinda K., additional, Alvand, Abtin, additional, Old, C. Fraser, additional, Bostock, Jennifer, additional, Paul, John, additional, Cooke, Graham, additional, Thwaites, Guy E., additional, Bejon, Philip, additional, and Scarborough, Matthew, additional

Published
2019
Full Text
View/download PDF

23. Comparing Conservative and Early Surgical Treatments for Pyogenic Spondylodiskitis: An International Propensity Score–Matched Retrospective Outcome Analysis

Author

Neuhoff, Jonathan, Kramer, Andreas, Thavarajasingam, Santhosh G., Sutherland, Rebecca K., McCaughan, Hugh, Joerger, Ann-Kathrin, Wostrack, Maria, Lyell, Barrie, Berkulian, Olga, Ponniah, Hariharan Subbiah, Ramsay, Daniele S. C., Meyer, Bernhard, Kandziora, Frank, Shiban, Ehab, Davies, Benjamin, Demetriades, Andreas K., and Ringel, Florian

Published
2024
Full Text
View/download PDF

24. Nocardiaand Actinomyces

Author

Henderson, Naomi M. and Sutherland, Rebecca K.

Abstract

Nocardiaand Actinomycesare Gram-positive bacteria of the order Actinomycetales. These ubiquitous organisms exhibit filamentous branching structures, which sometimes coalesce and develop into bundles known as mycelia. They are the cause of rare, but clinically important, infections and are often termed ‘the great masqueraders’. Affected individuals tend to present with chronic debilitating suppurative infections, and there can be a significant delay before a definitive diagnosis is made. Microbiological diagnosis is challenging, but advances in molecular techniques are improving the identification of these organisms. Despite the relative rarity of these conditions, an awareness of the disease manifestations caused by these organisms is beneficial; outcomes are more favourable if they are diagnosed early and effective treatment is initiated.

Published
2017
Full Text
View/download PDF

25. Nocardiaand Actinomyces

Author

Langoya, Charles OC, Henderson, Naomi M, and Sutherland, Rebecca K

Abstract

Nocardiaand Actinomycesare Gram-positive bacteria of the order Actinomycetales. These ubiquitous organisms exhibit filamentous branching structures, which sometimes coalesce and develop into bundles known as mycelia. They are the cause of rare, but clinically important, infections and are often termed ‘the great masqueraders’. Affected individuals tend to present with chronic debilitating suppurative infections, and there can be a significant delay before a definitive diagnosis is made; this calls for a high level of clinical vigilance. Microbiological diagnosis is challenging, but advances in molecular techniques are improving the identification of these organisms. Despite the relative rarity of these conditions, an awareness of the disease manifestations caused by these organisms is important because of their debilitating nature. In addition, outcomes are more favourable if they are diagnosed early and effective treatment is initiated in good time.

Published
2021
Full Text
View/download PDF

26. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Author

Emary, Katherine RW, Golubchik, Tanya, Aley, Parvinder K, Ariani, Cristina V, Angus, Brian John, Bibi, Sagida, Blane, Beth, Bonsall, David, Cicconi, Paola, Charlton, Sue, Clutterbuck, Elizabeth, Collins, Andrea M, Cox, Tony, Darton, Thomas, Dold, Christina, Douglas, Alexander D, Duncan, Christopher JA, Ewer, Katie, Flaxman, Amy, Faust, Saul N, Ferreira, Daniela M, Feng, Shuo, Finn, Adam, Folegatti, Pedro M, Fuskova, Michelle, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hallis, Bassam, Heath, Paul T, Hay, Jodie, Hill, Helen C, Jenkin, Daniel, Kerridge, Simon, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Ludden, Catherine, Marchevsky, Natalie, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Phillips, Daniel J, Plested, Emma, Pollock, Katrina M, Robinson, Hannah, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sutherland, Rebecca K, Thomson, Emma C, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Voysey, Merryn, Ramasamy, Maheshi N, Pollard, Andrew, Consortium, COVID-19 Genomics UK COG-UK, Group, Oxford COVID Vaccine Trial, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository

27. Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Author

Voysey, Merryn, Costa Clemens, Sue Ann, Madhi, Shabir A, Weckx, Lily Yin, Folegatti, Pedro M, Aley, Parvinder K, Angus, Brian John, Baillie, Vicky, Barnabas, Shaun L, Bhorat, Qasim E, Bibi, Sagida, Briner, Carmen, Cicconi, Paola, Clutterbuck, Elizabeth, Collins, Andrea M, Cutland, Clare, Darton, Thomas, Dheda, Keertan, Douglas, Alexander D, Duncan, Christopher JA, Emary, Katherine RW, Ewer, Katie, Flaxman, Amy, Fairlie, Lee, Faust, Saul N, Feng, Shuo, Ferreira, Daniela M, Finn, Adam, Galiza, Eva, Goodman, Anna L, Green, Catherine M, Green, Christopher A, Greenland, Melanie, Hill, Catherine, Hill, Helen C, Hirsch, Ian, Izu, Alane, Jenkin, Daniel, Kerridge, Simon, Koen, Anthonet, Kwatra, Gaurav, Lazarus, Rajeka, Libri, Vincenzo, Lillie, Patrick J, Marchevsky, Natalie, Marshall, Richard P, Mendes, Ana Verena Almeida, Milan, Eveline P, Minassian, Angela M, McGregor, Alastair C, Farooq Mujadidi, Yama, Nana, Anusha, Payadachee, Sherman D, Phillips, Daniel J, Pittella, Ana, Plested, Emma, Pollock, Katrina M, Ramasamy, Maheshi N, Robinson, Hannah, Schwarzbold, Alexandre V, Smith, Andrew, Song, Rinn, Snape, Matthew D, Sprinz, Eduardo, Sutherland, Rebecca K, Thomson, Emma C, Török, Mili Estée, Toshner, Mark, Turner, David PJ, Vekemans, Johan, Villafana, Tonya L, White, Thomas, Williams, Christopher J, Hill, Adrian VS, Lambe, Teresa, Gilbert, Sarah C, Pollard, Andrew, Group, Oxford COVID Vaccine Trial, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository

28. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Author

Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, and Pollard AJ

Subjects
Adolescent, Adult, Aged, Antibody Formation, Asymptomatic Infections, COVID-19 Vaccines adverse effects, ChAdOx1 nCoV-19, Humans, Middle Aged, Randomized Controlled Trials as Topic, SARS-CoV-2 immunology, Young Adult, COVID-19 prevention & control, COVID-19 Vaccines administration & dosage, COVID-19 Vaccines immunology, Immunization Schedule, Immunization, Secondary
Abstract

Background: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses. In addition, we show the immunogenicity and protection afforded by the first dose, before a booster dose has been offered., Methods: We present data from three single-blind randomised controlled trials-one phase 1/2 study in the UK (COV001), one phase 2/3 study in the UK (COV002), and a phase 3 study in Brazil (COV003)-and one double-blind phase 1/2 study in South Africa (COV005). As previously described, individuals 18 years and older were randomly assigned 1:1 to receive two standard doses of ChAdOx1 nCoV-19 (5 × 10 10 viral particles) or a control vaccine or saline placebo. In the UK trial, a subset of participants received a lower dose (2·2 × 10 10 viral particles) of the ChAdOx1 nCoV-19 for the first dose. The primary outcome was virologically confirmed symptomatic COVID-19 disease, defined as a nucleic acid amplification test (NAAT)-positive swab combined with at least one qualifying symptom (fever ≥37·8°C, cough, shortness of breath, or anosmia or ageusia) more than 14 days after the second dose. Secondary efficacy analyses included cases occuring at least 22 days after the first dose. Antibody responses measured by immunoassay and by pseudovirus neutralisation were exploratory outcomes. All cases of COVID-19 with a NAAT-positive swab were adjudicated for inclusion in the analysis by a masked independent endpoint review committee. The primary analysis included all participants who were SARS-CoV-2 N protein seronegative at baseline, had had at least 14 days of follow-up after the second dose, and had no evidence of previous SARS-CoV-2 infection from NAAT swabs. Safety was assessed in all participants who received at least one dose. The four trials are registered at ISRCTN89951424 (COV003) and ClinicalTrials.gov, NCT04324606 (COV001), NCT04400838 (COV002), and NCT04444674 (COV005)., Findings: Between April 23 and Dec 6, 2020, 24 422 participants were recruited and vaccinated across the four studies, of whom 17 178 were included in the primary analysis (8597 receiving ChAdOx1 nCoV-19 and 8581 receiving control vaccine). The data cutoff for these analyses was Dec 7, 2020. 332 NAAT-positive infections met the primary endpoint of symptomatic infection more than 14 days after the second dose. Overall vaccine efficacy more than 14 days after the second dose was 66·7% (95% CI 57·4-74·0), with 84 (1·0%) cases in the 8597 participants in the ChAdOx1 nCoV-19 group and 248 (2·9%) in the 8581 participants in the control group. There were no hospital admissions for COVID-19 in the ChAdOx1 nCoV-19 group after the initial 21-day exclusion period, and 15 in the control group. 108 (0·9%) of 12 282 participants in the ChAdOx1 nCoV-19 group and 127 (1·1%) of 11 962 participants in the control group had serious adverse events. There were seven deaths considered unrelated to vaccination (two in the ChAdOx1 nCov-19 group and five in the control group), including one COVID-19-related death in one participant in the control group. Exploratory analyses showed that vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 after vaccination was 76·0% (59·3-85·9). Our modelling analysis indicated that protection did not wane during this initial 3-month period. Similarly, antibody levels were maintained during this period with minimal waning by day 90 (geometric mean ratio [GMR] 0·66 [95% CI 0·59-0·74]). In the participants who received two standard doses, after the second dose, efficacy was higher in those with a longer prime-boost interval (vaccine efficacy 81·3% [95% CI 60·3-91·2] at ≥12 weeks) than in those with a short interval (vaccine efficacy 55·1% [33·0-69·9] at <6 weeks). These observations are supported by immunogenicity data that showed binding antibody responses more than two-fold higher after an interval of 12 or more weeks compared with an interval of less than 6 weeks in those who were aged 18-55 years (GMR 2·32 [2·01-2·68])., Interpretation: The results of this primary analysis of two doses of ChAdOx1 nCoV-19 were consistent with those seen in the interim analysis of the trials and confirm that the vaccine is efficacious, with results varying by dose interval in exploratory analyses. A 3-month dose interval might have advantages over a programme with a short dose interval for roll-out of a pandemic vaccine to protect the largest number of individuals in the population as early as possible when supplies are scarce, while also improving protection after receiving a second dose., Funding: UK Research and Innovation, National Institutes of Health Research (NIHR), The Coalition for Epidemic Preparedness Innovations, the Bill & Melinda Gates Foundation, the Lemann Foundation, Rede D'Or, the Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca., (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)

Published
2021
Full Text
View/download PDF

29. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Author

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, and Pollard AJ

Subjects
Adolescent, Adult, Aged, Brazil, ChAdOx1 nCoV-19, Double-Blind Method, Female, Humans, Male, Middle Aged, Single-Blind Method, South Africa, Treatment Outcome, United Kingdom, Young Adult, COVID-19 prevention & control, COVID-19 Vaccines adverse effects
Abstract

Background: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials., Methods: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 10 10 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674., Findings: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; p interaction =0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation., Interpretation: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials., Funding: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca., (Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results